Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price ...
TD Cowen Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The company’s shares closed ...
Lockheed Martin Just Lost a Multibillion-Dollar Deal -- but All Hope Is Not Lost
Lockheed Martin Just Lost a Multibillion-Dollar Deal -- but All Hope Is Not Lost was originally published by The Motley Fool ...
GameRant on MSN5d
Upcoming Switch Games Releasing In 2024 & Beyond
The Nintendo Switch's library is vast and constantly growing. Here is every major new Switch game releasing in 2024 or beyond ...